RGNX vs RNAC

REGENXBIO Inc. vs Cartesian Therapeutics, Inc. — Valuation Comparison 2026

RGNX

Biotechnology
REGENXBIO Inc.
Quality
6.4
out of 10
Value Trap
18
SAFE
Price
$6.89
Last close
Models
9/13
Active
VS

RNAC

Biotechnology
Cartesian Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
39
LOW
Price
$7.21
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType RGNX Fair ValueRGNX Upside RNAC Fair ValueRNAC Upside
Bayesian DCF Intrinsic $0.88 -87.3% $5.09 -28.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.93 -72.0%
PWERM Option-Based $11.34 +64.6% $10.81 +49.9%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RGNX vs RNAC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RGNX vs RNAC — Which Stock Is More Undervalued?

RGNX scores higher with a 6.4/10 quality rating vs RNAC's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing REGENXBIO Inc. (RGNX) and Cartesian Therapeutics, Inc. (RNAC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RGNX currently trades at $6.89 with a QOC of 6.4/10, while RNAC trades at $7.21 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).